A new research finding related to a less costly and more convenient treatment for Gaucher's disease, the most common lysosomal storage disorder and genetic disorder affecting Jewish people of Eastern European ancestry is reported. The reports suggest that chemical chaperons could partially correct the genetic defect responsible for most cases of Gaucher's disease and compared to earlier enzyme replacement therapy for treatment costing $100,000-$750,000 annually, the new research could cut those costs to $1000-$7500 annually.